Author(s):
Sandip Vadariya, Jigar Patel, Haresh Patel, Hitin Hirpara
Email(s):
pramukhprit@gmail.com
DOI:
10.52711/0974-360X.2026.00214 
Address:
Sandip Vadariya1, Jigar Patel2*, Haresh Patel1, Hitin Hirpara3
1Analytical Research Development, Cohance Lifesciences Limited API RandD Centre, Ankleshwar, 393002, India.
2Deputy Director (Technical), Sophisticated Instrumentation Centre for Applied Research and Testing – SICART, Vallabh Vidyanagar, Anand, 388120, India.
3Research and Development Department, Cohance Lifesciences Limited API RandD Centre, Ankleshwar, 393002, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 4,
Year - 2026
ABSTRACT:
Currently, all the pharmaceutical industries and related industries have been dealing with issue from nitrosamine drug substance related impurities (NDSRIs) due to their potential health risks. Regulatory agencies provide guidelines for essential detail for generation pathways of their formation, severity, and permissible limits for human consumption. This research presents a trace-level quantification and identification, rapid, and high-sensitive LC-MS/MS technique for N-nitroso-mirabegron (NDSRIs) impurity in mirabegron with a LOQ of 0.8 µg/mL. The QSAR results are positive for N-nitroso-mirabegron, and the cohort of concern (CoC) suggests possible genotoxicity. Inert Sustain PFP (4.6mm x 150mm), 5µ HPLC column and mobile phase A contain 0.63 g/L of ammonium format, methanol, and acetonitrile in a 4:3:3 (v/v/v) ratio while mobile phase B contain 0.2% formic acid in methanol. Positive ionization in Electron spray ionization (ESI) and multiple reaction monitoring (MRM) detection uses for identification and quantification. Linearity range of 0.8µg/mL to 12µg/mL with regression coefficient >0.990, precision (%RSD = 1.8, %RSD of Method precision = 3.01 and Intermediate Precision = 5.47). Accuracy within the range 84.55 – 91.64% within limit. While screening mirabegron samples for NDSRIs, the presence of N-nitroso-mirabegron was detected.
Cite this article:
Sandip Vadariya, Jigar Patel, Haresh Patel, Hitin Hirpara. Trace-Level Quantification and Identification of Mutagenic and Cohort-of-Concern N-nitroso-mirabegron Impurity (NDSRIs) using UFLC-ESI-MS/MS in Mirabegron. Research Journal of Pharmacy and Technology. 2026;19(4):1492-8. doi: 10.52711/0974-360X.2026.00214
Cite(Electronic):
Sandip Vadariya, Jigar Patel, Haresh Patel, Hitin Hirpara. Trace-Level Quantification and Identification of Mutagenic and Cohort-of-Concern N-nitroso-mirabegron Impurity (NDSRIs) using UFLC-ESI-MS/MS in Mirabegron. Research Journal of Pharmacy and Technology. 2026;19(4):1492-8. doi: 10.52711/0974-360X.2026.00214 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-4-3
8. REFERENCES:
1. Dawood O, El-Zawahry A. Mirabegron. In: StatPearls. StatPearls Publishing; 2025. Accessed August 29, 2025. http://www.ncbi.nlm.nih.gov/books/NBK538513/
2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
3. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R1).
4. ICH Harmonised Guideline. Published March 31, 2017. Accessed August 29, 2025.
5. Available from: https://database.ich.org/sites/default/files/M7_R1_Guideline.pdf
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
7. Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R2).
8. ICH Harmonised Guideline. Published April 3, 2023. Accessed August 29, 2025.
9. Available from: https://database.ich.org/sites/default/files/ICH_M7%28R2%29_Guideline_Step4_2023_0216_0.pdf
10. Bharate SS. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. J Med Chem. 2021; 64(6): 2923-2936. doi: 10.1021/acs.jmedchem.0c02120
11. US Food and Drug Administration. Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of All Irbesartan Tablets and Irbesartan and Hydrochlorothiazide Tablets Due to Potential Presence of N-nitrosoirbesartan Impurity. Published October 14, 2021. Accessed September 1, 2025. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/lupin-pharmaceuticals-inc-issues-voluntarily-nationwide-recall-all-irbesartan-tablets-and-irbesartan
12. US Food and Drug Administration. Pfizer Expands Voluntary Nationwide Recall to Include All Lots of CHANTIX® (Varenicline) Tablets Due to N-Nitroso Varenicline Content. Published September 16, 2021. Accessed September 1, 2025. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/pfizer-expands-voluntary-nationwide-recall-include-all-lots-chantixr-varenicline-tablets-due-n
13. US Food and Drug Administration. Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended-Release Tablets Due to Presence of a Nitrosamine Impurity. Published March 22, 2022. Accessed September 1, 2025. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-13-lots-orphenadrine-citrate-100-mg-extended-release-tablets-due
14. Health Canada. Pfizer recalls Inderal-LA (propranolol hydrochloride) capsules due to a nitrosamine impurity. Published March 1, 2022. Accessed September 1, 2025. https://recalls-rappels.canada.ca/en/alert-recall/pfizer-recalls-inderal-propranolol-hydrochloride-capsules-due-nitrosamine-impurity
15. Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N -Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective on Risk Factors and Mitigation Strategies. Org Process Res Dev. 2023; 27(10): 1736-1750. doi:10.1021/acs.oprd.3c00153
16. European Medicines Agency. Appendix 1 to Questions and Answers for Marketing Authorisation Holders/Applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 Referral on Nitrosamine Impurities in Human Medicinal Products: Acceptable Intakes Established for N-Nitrosamines. Published July 7, 2023. Accessed October 24, 2023. Holzgrabe U. Nitrosated Active Pharmaceutical Ingredients – Lessons Learned? Journal of Pharmaceutical Sciences. 2023; 112(5): 1210-1215. doi:10.1016/j.xphs.2023.01.021
17. US Food and Drug Administration. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs): Guidance for Industry. Center for Drug Evaluation and Research (CDER); August 2023. Accessed September 1, 2025. https://www.fda.gov/media/170794/download
18. Ashworth IW, Dirat O, Teasdale A, Whiting M. Potential for the Formation of N Nitrosamines during the Manufacture of Active Pharmaceutical Ingredients: An Assessment of the Risk Posed by Trace Nitrite in Water. Org Process Res Dev. 2020;24(9):1629-1646. doi:10.1021/acs.oprd.0c00224
19. Horne S, Vera MD, Nagavelli LR, Sayeed VA, Heckman L, Johnson D, Berger D, Yip YY, Krahn CL, Sizukusa LO, Rocha NFM, Bream RN, Ludwig J, Keire DA, Condran G. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals. Journal of Pharmaceutical Sciences. 2023; 112(5): 1166-1182. doi:10.1016/j.xphs.2022.12.022
20. Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, Blom G, Harrison M, François M, Allain L, Wu Y, Bousraf Y. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products. Journal of Pharmaceutical Sciences. 2023; 112(6): 1615-1624. doi:10.1016/j.xphs.2022.04.016
21. Control of impurities of pharmacopoeial substances - Scientific guideline | European Medicines Agency (europa.eu) International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, S2 (R1) 2011; https://database.ich.org/sites/default/files/S2_R1_Guideline.pdf.
22. National Pharmacopoeia Commission. Guidelines for the Control of Genotoxic Impurities (First draft) 2019 https://www.chp.org.cn/ydw/upload/userfiles/20190123/641548209919095.pdf
23. US Food and Drug Administration. Control of Nitrosamine Impurities in Human Drugs: Guidance for Industry. Center for Drug Evaluation and Research (CDER). September 2024. Revision 2. Accessed September 1, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/control-nitrosamine-impurities-human-drugs
24. Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, Horne S, King ST, Koval IA, Kumaran G, Langenkamp A, McGovern TJ, Peryea T, Sanh A, Siqueira Ferreira A, Van Aerts L, Vespa A, Whomsley R. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regulatory Toxicology and Pharmacology. 2024; 150: 105640. doi:10.1016/j.yrtph.2024.105640
25. Burns MJ, Ponting DJ, Foster RS, Thornton BP, Romero NE, Smith GF, Ashworth IW, Teasdale A, Simon S, Schlingemann J. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals. Journal of Pharmaceutical Sciences. 2023; 112(12): 3005-3011. doi:10.1016/j.xphs.2023.10.001
26. Nakka S, Katari NK, Muchakayala SK, Jonnalagadda SB, Manabolu Surya SB. Synthesis and Trace-Level Quantification of Mutagenic and Cohort-of-Concern Ciprofloxacin Nitroso Drug Substance-Related Impurities (NDSRIs) and Other Nitroso Impurities Using UPLC-ESI-MS/MS─Method Optimization Using I-Optimal Mixture Design. ACS Omega. 2024; 9(8): 8773-8788. doi:10.1021/acsomega.3c05170
27. Chidella KS, Dasari VB, Anireddy J. Ultra-Sensitive LC-MS/MS Method for the Trace Level Quantification of Six Potential Genotoxic Nitrosamine Impurities in Telmisartan. AJAC. 2021; 12(06): 227-240. doi:10.4236/ajac.2021.126014
28. Nakka S, Muchakayala SK, Manabolu Surya SB. A novel and eco-friendly UPLC-ESI-MS method for the quantification of Aceclofenac-NDSRI (Nitroso Drug Substance Related Impurity) from Aceclofenac drug substance and combination formulations. Sustainable Chemistry and Pharmacy. 2024; 38: 101495. doi:10.1016/j.scp.2024.101495
29. Gopireddy RR, Maruthapillai A, Mahapatra S. A Multi-Analyte LC–MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan. Journal of Chromatographic Science. 2024; 62(2): 147-167. doi:10.1093/chromsci/bmac059
30. Malihi F, Wang T. An improved analytical method for quantitation of nitrosamine impurities in ophthalmic solutions using liquid chromatography with tandem mass spectrometry. Journal of Chromatography Open. 2022; 2:100037. doi:10.1016/j.jcoa.2022.100037